Cargando…
Interactions of IgG1 CH2 and CH3 Domains with FcRn
Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/ https://www.ncbi.nlm.nih.gov/pubmed/24765095 http://dx.doi.org/10.3389/fimmu.2014.00146 |
_version_ | 1782310815993430016 |
---|---|
author | Ying, Tianlei Ju, Tina W. Wang, Yanping Prabakaran, Ponraj Dimitrov, Dimiter S. |
author_facet | Ying, Tianlei Ju, Tina W. Wang, Yanping Prabakaran, Ponraj Dimitrov, Dimiter S. |
author_sort | Ying, Tianlei |
collection | PubMed |
description | Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure–activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives, and other favorable biophysical properties for their druggability. |
format | Online Article Text |
id | pubmed-3980117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-39801172014-04-24 Interactions of IgG1 CH2 and CH3 Domains with FcRn Ying, Tianlei Ju, Tina W. Wang, Yanping Prabakaran, Ponraj Dimitrov, Dimiter S. Front Immunol Immunology Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome this problem is through the development of novel antibody fragments based on IgG Fc region, which contributes to the long half-life of IgG through its unique pH-dependent association with the neonatal Fc receptor (FcRn). The IgG Fc region comprises two CH2 and two CH3 domains. In this report, we present a comparative study of the FcRn binding capability of the CH2 and CH3 domains. The stability and aggregation resistance of these domains were also investigated and compared. We found that monomeric CH2 and CH3 domains exhibited the pH-dependent FcRn binding while the dimeric forms of CH2 and CH3 domains did not. Although all of these domains had high serum stability, they had aggregation tendencies as measured by dynamic light scattering. By providing a better understanding of the structure–activity relationship of the Fc fragment, these results guide further approaches to generate novel Fc-based small-size antibody fragments that possess pH-dependent FcRn binding capability, desired in vivo half-lives, and other favorable biophysical properties for their druggability. Frontiers Media S.A. 2014-04-02 /pmc/articles/PMC3980117/ /pubmed/24765095 http://dx.doi.org/10.3389/fimmu.2014.00146 Text en Copyright © 2014 Ying, Ju, Wang, Prabakaran and Dimitrov. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ying, Tianlei Ju, Tina W. Wang, Yanping Prabakaran, Ponraj Dimitrov, Dimiter S. Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title_full | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title_fullStr | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title_full_unstemmed | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title_short | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
title_sort | interactions of igg1 ch2 and ch3 domains with fcrn |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/ https://www.ncbi.nlm.nih.gov/pubmed/24765095 http://dx.doi.org/10.3389/fimmu.2014.00146 |
work_keys_str_mv | AT yingtianlei interactionsofigg1ch2andch3domainswithfcrn AT jutinaw interactionsofigg1ch2andch3domainswithfcrn AT wangyanping interactionsofigg1ch2andch3domainswithfcrn AT prabakaranponraj interactionsofigg1ch2andch3domainswithfcrn AT dimitrovdimiters interactionsofigg1ch2andch3domainswithfcrn |